Charles Schwab stock rises after TD Cowen raises price target on buyback

Charles Schwab (SCHW) announced a new $20 billion share repurchase program, replacing a prior $15 billion authorization, signaling enhanced capital return and balance sheet optimization. This follows stronger-than-expected Q2 2025 adjusted EPS of $1.14, which prompted TD Cowen to raise its price target to $129 and other firms like Citi, JMP, and KBW to also increase their targets. Analysts have broadly revised earnings estimates upward, reinforcing the company's strong financial performance and strategic initiatives, including expanded overnight trading services.

Analysis

Charles Schwab (SCHW) has demonstrated significant positive momentum, underscored by a new, upsized $20 billion share repurchase authorization. This program, which is 33% larger than its predecessor and represents approximately 11% of the company's market capitalization, signals a strong commitment to enhancing capital returns and is viewed by analysts as a driver for earnings per share accretion and a sign of declining balance sheet intensity. This strategic capital decision is supported by robust financial performance, evidenced by the second-quarter 2025 adjusted EPS of $1.14, which surpassed the consensus estimate of $1.09. The earnings beat has triggered a wave of positive sentiment from the analyst community, with TD Cowen raising its price target to $129 and firms like Citi, JMP, and Keefe, Bruyette & Woods also increasing their targets. The consensus is further reinforced by 16 analysts revising earnings estimates upward for the upcoming period. Fundamentally, the company's stability is highlighted by an InvestingPro "GOOD" financial health score and an uninterrupted 37-year history of dividend payments. Combined with a 32% year-to-date stock return and strategic service enhancements like expanded 24-hour trading, the developments paint a picture of a company executing effectively on both financial management and operational growth.

Key Decisions for Investors

• Investors should view the new $20 billion share repurchase program, equivalent to 11% of market capitalization, as a significant catalyst for EPS accretion and a strong signal of management's confidence in future cash flow.
• The broad consensus of positive analyst revisions and price target increases from multiple firms, including TD Cowen's new $129 target, provides strong third-party validation of the company's positive trajectory following its earnings outperformance.
• Despite the stock's 32% year-to-date return and proximity to its 52-week high, the company's 'GOOD' financial health rating and 37-year dividend track record provide fundamental support for its valuation.
• It is prudent to monitor the execution pace of the substantial buyback program and the impact of strategic initiatives, such as expanded trading hours, as key indicators of sustained operational and financial momentum.